Vancouver, British Columbia, September 08, 2021 – Genix Pharmaceuticals Corporation (TSX-V: GENX; OTCQB: GENPF) (“GENIX” or the “Company”) is pleased to announce that it has recently received Health Canada registration approval and has been issued a Natural Product Number (NPN) for Rechlor (Renolchlor®) – which aids in restoring kidney health and kidney functions naturally.
In 2020, Genix acquired the Canadian sales and marketing rights for Renochlor® and will be renamed “Rechlor” for the purpose of sales in the Canadian market. The NPN for Rechlor issued to Genix is 80112398 which has been approved for distribution to patients, naturopathic doctors and pharmacies throughout Canada.
Rechlor is a clinically proven dietary supplement for improvement of renal functions in patients suffering from Chronic Renal Failure (CRF) and Chronic Kidney Disease (CKD). According to the Kidney Foundation of Canada, one-in-ten Canadians, or some 4 million people, suffer from kidney disease which if not treated will ultimately lead to kidney failure and the need for permanent dialysis or kidney transplant. Rechlor is the first-in-class natural over-the-counter product to effectively address both CKD and CRF with no known side effects or adverse reactions.
- Protects kidneys from various nephrotoxins (renal toxicity)
- Assists in reduction of serum creatinine and blood urea levels
- Aid in improvement of glomerular filtration rate
- A novel therapy for renal care
- A dietary supplement acting as nephroprotective, antioxidant, immune booster
- Clinical trials suggest improvement of quality of life in CRF patients
Mr. Mahmoud Aziz- President, states “We are extremely pleased to have received Health Canada approval for Rechlor as it allows Genix to begin sales in Canada immediately. Until now, people have only had the option of facing the bleak prognosis of having expensive and inconvenient kidney dialysis or kidney transplant. Based on the scientific studies and clinical trials conducted on this product, we believe Rechlor will help Canadians suffering from kidney disease, whether it be Chronic Kidney Disease or Chronic Renal Failure.”
Genix Pharmaceuticals Corporation is a highly innovative, Canadian life-sciences company focused on the manufacturing, acquisition, sales and distribution of the leading and widely used ophthalmological drugs and single source generic prescription and OTC pharmaceuticals and in the research & development of novel, innovative ophthalmological pharmaceuticals to satisfy large and unmet consumer/patient needs
Mr. Mahmoud Aziz,
President & Director
Genix Pharmaceuticals Corporation
For more information regarding GENIX, please contact:
Kevin Bottomley, Director
Tel: +1 (604) 609.6199
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, “forward‐looking statements”. Forward‐looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward‐looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward‐looking statements.